Please login to the form below

Not currently logged in
Email:
Password:

patent cliff

This page shows the latest patent cliff news and features for those working in and with pharma, biotech and healthcare.

Pricing pressures peg back Lilly’s growth products

Pricing pressures peg back Lilly’s growth products

Lilly has other new medicines rolling out to help it manage the Cialis patent cliff, and third-to-market CGRP inhibitor for migraine – Emgality (galcanezumab) - added $14m in the quarter, overtaking

Latest news

  • Takeda’s Entyvio tops Humira in ulcerative colitis Takeda’s Entyvio tops Humira in ulcerative colitis

    Entyvio is an important growth product for Takeda as it is bearing the brunt of losing patent protection in the US for its big-selling multiple myeloma drug Velcade (bortezomib). ... Takeda’s patent cliff and a weak near-term pipeline were the main

  • BMS trades blows with investor on Celgene deal merits BMS trades blows with investor on Celgene deal merits

    The activist investors claim that BMS is buying a company with a massive patent cliff – principally blood cancer blockbuster Revlimid (lenalidomide) – which they say will requite Celgene to replace 60% of

  • Pfizer builds gap between pharma and consumer health units Pfizer builds gap between pharma and consumer health units

    Pfizer CEO described the move as a “natural evolution” for the group as it looks to life beyond 2020 – after which it will have dealt with most of its ‘patent cliff’ –

  • Lundbeck and Otsuka start phase III for Rexulti in bipolar Lundbeck and Otsuka start phase III for Rexulti in bipolar

    off the patent cliff in recent years and seen steep sales decline as a result, although a long-acting depot formulation (Abilify Maintena) is still making gains. ... Rexulti is one of a string of new drugs at Lundbeck - along with Abilify and

  • Life lessons Life lessons

    In the case of generics, we’re seeing four variations emerge. Fast followers, like the biosimilar companies, compete by living very close to the edge of the patent cliff.

More from news
Approximately 3 fully matching, plus 47 partially matching documents found.

Latest Intelligence

  • Mylan sees the UK paving the way for an insulin game changer Mylan sees the UK paving the way for an insulin game changer

    The dream is that, on Day One when the product loses its patent, 100% of the patients use the biosimilar and the opportunity has been optimised. ... biosimilar and the promise of Mylan’s pipeline, which is fuelled by an annual Research &Development

  • Change in the pharma industry is inevitable Change in the pharma industry is inevitable

    The industry’s patent cliff is nothing new but the targeted, specialist nature of the latest generation of drugs is making it increasingly challenging to deliver a return on investment within ... the 10-year window that a patent is in force.

  • Building a bright future Building a bright future

    the patent cliff of high-value biologics across Europe. ... We are in the front of a big patent cliff which creates a tremendous opportunity.”.

  • Pharma deals during August 2014 Pharma deals during August 2014

    Will the fools or angels win out? The prospect of lost revenues resulting from Lantus' tumble off the patent cliff next year seems to be sufficient motivation for Sanofi, one of

  • Back to the future Back to the future

    And at the same time, the impact of generic erosion and the patent cliff continues to wipe billions of dollars off their shareholder value. ... The leaders in pharma showed high levels of resilience through 2013, despite the continuing fallout from the

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics